

Madrid, March 19, 2026

LABIANA HEALTH, S.A. (hereinafter, the “Company”), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, and in accordance with the provisions of Article 227 of Law 6/2023 of March 17 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, regarding information to be provided by companies listed for trading on said segment, hereby announces the following:

#### **OTHER RELEVANT INFORMATION**

Further to the “inside information” disclosure dated February 18, 2026, regarding the agreement to carry out a capital increase, the Company announces that this process was successfully completed today, following the full subscription of the maximum planned amount of 5,072,000 euros.

During the periods for preemptive subscription, allocation of additional shares, and the discretionary allocation period, a total of 1,268,000 shares of the Company were subscribed. It should be noted that the transaction was significantly oversubscribed, with demand exceeding the number of shares subject to the increase by 50%, which required the application of the pro-rata allocation mechanisms provided for in the terms of the capital increase.

The corresponding notarized deed of the capital increase was executed today and filed for registration with the Madrid Commercial Registry; once registered, the necessary procedures will be carried out to list the new shares for trading on BME Growth.

In compliance with the provisions of Circular 3/2020 of BME MTF Equity, it is hereby expressly stated that the information disclosed herein has been prepared under the sole responsibility of the Company and its directors.

We remain at your disposal for any further clarification you may require.

Sincerely,

Mr. Manuel Ramos Ortega  
Chief Executive Officer  
LABIANA HEALTH, S.A.